Evidence map›Paper›PMID 35454897›Full record

ArticleCancers2022

SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence.

Namjeong Choi, Ha Na Jang, Jagyeong Oh, Jiyeon Ha, Hyungbin Park, Xuexiu Zheng, Sunjae Lee, Haihong Shen

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Targeting RNA splicing modulation: new perspectives for anticancer strategy?Journal of experimental & clinical cancer research : CR · 2025
    Review
  4. NSUN2-mediated mTheranostics · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Namjeong ChoiSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Ha Na JangSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Jagyeong OhSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Jiyeon HaSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Hyungbin ParkSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Xuexiu ZhengSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Sunjae LeeSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.ORCID 0000-0002-6428-5936
Haihong ShenSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
Gwangju Institute of Science and Technology · KR

Funding

Bio-Synergy Research Project 2021M3A9C4000991GIST GIST Research Institute (GRI) GIST-MIT research Collaboration grantGIST GIST Research Institute (GRI) IIBRNational Research Foundation ICTthe Ministry of Education and the National Research Foundation of Korea 2016R1A5A1007318the Ministry of Education and the National Research Foundation of Korea NRF-2019R1I1A1A01057372the Ministry of Education and the National Research Foundation of Korea NRF-2020R1A2C2004682
6 · The paper itself

Abstract

Alternative splicing (AS) is a procedure during gene expression that allows the production of multiple mRNAs from a single gene, leading to a larger number of proteins with various functions. The alternative splicing (AS) of Fas (Apo-1/CD95) pre-mRNA can generate membrane-bound or soluble isoforms with pro-apoptotic and anti-apoptotic functions. SRSF6, a member of the Serine/Arginine-rich protein family, plays essential roles in both constitutive and alternative splicing. Here, we identified SRSF6 as an important regulatory protein in Fas AS. The cassette exon inclusion of Fas was decreased by SRSF6-targeting shRNA treatment, but increased by SRSF6 overexpression. The deletion and substitution mutagenesis of the Fas minigene demonstrated that the UGCCAA sequence in the cassette exon of the Fas gene causes the functional disruption of SRSF6, indicating that these sequences are essential for SRSF6 function in Fas splicing. In addition, biotin-labeled RNA-pulldown and immunoblotting analysis showed that SRSF6 interacted with these RNA sequences. Mutagenesis in the splice-site strength alteration demonstrated that the 5' splice-site, but not the 3' splice-site, was required for the SRSF6 regulation of Fas pre-mRNA. In addition, a large-scale RNA-seq analysis using GTEX and TCGA indicated that while SRSF6 expression was correlated with Fas expression in normal tissues, the correlation was disrupted in tumors. Furthermore, high SRSF6 expression was linked to the high expression of pro-apoptotic and immune activation genes. Therefore, we identified a novel RNA target with 5' splice-site dependence of SRSF6 in Fas pre-mRNA splicing, and a correlation between SRSF6 and Fas expression.

Indexed as

alternative splicingFasSRSF6

Identifiers

PMID35454897
PMCPMC9025165
OpenAlexW4224056777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.